Form 4: AnaptysBio Director John P. Schmid Acquires Stock Options and Restricted Stock Units

Director John P. Schmid of AnaptysBio, Inc. was granted stock options and restricted stock units on January 7, 2025.

Summary

• On January 7, 2025, John P. Schmid, a director at AnaptysBio, Inc., acquired 16,510 stock options with an exercise price of $14.83.
• These stock options vest monthly starting February 7, 2025, over a 12-month period, contingent on continued service to the company.
• Schmid also received 6,030 restricted stock units (RSUs), each representing one share of common stock.
• The RSUs will vest fully on the date of the company's 2026 annual meeting of shareholders, also subject to continued service.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation for a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedules for both the options and RSUs incentivize continued service and commitment from the director.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to incentivize and retain key personnel, including directors.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for director compensation in publicly traded biotech companies.
• Vesting schedules are typically structured to align with long-term company performance and director retention, similar to other companies in the sector.

Stakeholder Impact

• The grants of stock options and RSUs to a director may be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

stock options, restricted stock units, director, insider trading, equity compensation, AnaptysBio, ANAB